Heron Therapeutics (HRTX) Given “Buy” Rating at Mizuho

Mizuho reiterated their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX) in a research note published on Tuesday. They currently have a $28.00 price objective on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Cowen reaffirmed a buy rating and issued a $40.00 price target on shares of Heron Therapeutics in a research note on Monday, November 6th. Cantor Fitzgerald reaffirmed a buy rating and issued a $31.00 price target on shares of Heron Therapeutics in a research note on Thursday, November 2nd. Oppenheimer initiated coverage on Heron Therapeutics in a research note on Monday, October 30th. They issued a buy rating and a $27.00 price target on the stock. Noble Financial reaffirmed a buy rating and issued a $24.00 price target on shares of Heron Therapeutics in a research note on Friday, October 6th. Finally, Zacks Investment Research raised Heron Therapeutics from a hold rating to a buy rating and set a $18.00 price target on the stock in a research note on Wednesday, November 22nd. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of Buy and an average target price of $28.82.

Heron Therapeutics (NASDAQ HRTX) remained flat at $$21.40 on Tuesday. 1,294,900 shares of the company traded hands, compared to its average volume of 1,101,430. The firm has a market capitalization of $1,180.00, a P/E ratio of -5.65 and a beta of 2.12. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a 1 year low of $12.25 and a 1 year high of $22.20.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The business had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. sell-side analysts forecast that Heron Therapeutics will post -3.38 EPS for the current year.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 19.93% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Private Asset Management Inc. boosted its stake in Heron Therapeutics by 190.6% in the fourth quarter. Private Asset Management Inc. now owns 86,975 shares of the biotechnology company’s stock worth $1,574,000 after purchasing an additional 57,050 shares in the last quarter. Rubric Capital Management LP boosted its stake in Heron Therapeutics by 11.8% in the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after purchasing an additional 200,000 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Heron Therapeutics in the third quarter worth $5,329,000. Janus Henderson Group PLC boosted its stake in Heron Therapeutics by 2.2% in the third quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock worth $93,145,000 after purchasing an additional 126,039 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Heron Therapeutics in the third quarter worth $223,000. 98.21% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/01/17/heron-therapeutics-hrtx-given-buy-rating-at-mizuho.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply